Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the efficacy and safety of the fixed dose combination of
telmisartan 80 mg + hydrochlorothiazide 25 mg (T80/H25) alone or in addition to other
antihypertensive therapies during open-label, long-term treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Hydrochlorothiazide Telmisartan Telmisartan, hydrochlorothiazide drug combination